At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of non-small cell lung cancer (NSCLC)
- ✓Average weight loss of at least 5% within 2 months prior to enrollment
- ✓Heart rate of 72 bpm or greater
- ✓Expected survival of at least 12 weeks
- ✕Contraindication to NSAIDs or beta-blockers
- ✕Weight loss of 15% or greater within 2 months prior to recruitment
- ✕History of myocardial infarction within the past 3 months
- ✕Congestive heart failure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Open Label Randomized Controlled Study to Evaluate the Dose Tolerance Safety and Efficacy of VT-122 Regimen for the Treatment of Cachexia in Subjects With Stage IV Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating VT-122 low dose and VT-122 high dose for Cachexia. Completed, enrolled 37 participants across 8 sites in 2 countries.
Detailed Summary
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not utilized. To switch the nutritional system from a hypercatabolic to a normal nutritional state, therapy must block multi-factorial stress signaling a threshold of activation. Consistent with the synergistic hypothesis, propranolol and etodolac have been evaluated in subjects with advanced cancer demonstrating cachexia. This trial will evaluate the safety and efficacy of VT-122 in subjects with NSCLC who have hypercatabolic cachexia.
Study Details
Timeline
Interventions
VT-122 low dose, dose escalated
VT-122 high dose, dose escalated